Olaparib, the first FDA-approved PARP inhibitor, has been approved as an adjuvant treatment option for HR+/HER2- ABC with germline BRCA1 or BRCA2 mutations or early-stage, high-risk breast cancer that has received neoadjuvant or adjuvant chemotherapy. Here, BRCA1 is linked to breast cancer.